These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 18283630)

  • 1. Targeted cellular therapy with natural killer cells.
    Klingemann H; Boissel L
    Horm Metab Res; 2008 Feb; 40(2):122-5. PubMed ID: 18283630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer.
    Ruggeri L; Mancusi A; Capanni M; Martelli MF; Velardi A
    Curr Opin Immunol; 2005 Apr; 17(2):211-7. PubMed ID: 15766683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK cell receptors as tools in cancer immunotherapy.
    Sentman CL; Barber MA; Barber A; Zhang T
    Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cells in cancer immunotherapy: three decades of discovery.
    Boyiadzis M; Foon KA; Herberman RB
    Discov Med; 2006 Dec; 6(36):243-8. PubMed ID: 17250791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human natural killer cells: a comprehensive review.
    Sinkovics JG; Horvath JC
    Int J Oncol; 2005 Jul; 27(1):5-47. PubMed ID: 15942642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human natural killer cells in health and disease.
    Shereck E; Satwani P; Morris E; Cairo MS
    Pediatr Blood Cancer; 2007 Oct; 49(5):615-23. PubMed ID: 17265453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges of cancer therapy with natural killer cells.
    Klingemann H
    Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology of natural killer cells and implications for therapy of human disease.
    Chiorean EG; Miller JS
    J Hematother Stem Cell Res; 2001 Aug; 10(4):451-63. PubMed ID: 11522229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy.
    Gupta N; Arthos J; Khazanie P; Steenbeke TD; Censoplano NM; Chung EA; Cruz CC; Chaikin MA; Daucher M; Kottilil S; Mavilio D; Schuck P; Sun PD; Rabin RL; Radaev S; Van Ryk D; Cicala C; Fauci AS
    Virology; 2005 Feb; 332(2):491-7. PubMed ID: 15680414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cell-based immunotherapeutic strategies.
    Klingemann HG
    Cytotherapy; 2005; 7(1):16-22. PubMed ID: 16040380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell tolerance licensing and other mechanisms.
    Jonsson AH; Yokoyama WM
    Adv Immunol; 2009; 101():27-79. PubMed ID: 19231592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.
    Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A
    Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cell-directed therapies: moving from unexpected results to successful strategies.
    Terme M; Ullrich E; Delahaye NF; Chaput N; Zitvogel L
    Nat Immunol; 2008 May; 9(5):486-94. PubMed ID: 18425105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do natural killer cells find self to achieve tolerance?
    Yokoyama WM; Kim S
    Immunity; 2006 Mar; 24(3):249-57. PubMed ID: 16546094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling killers; unravelling the pathways of human natural killer cell function.
    Scott GB; Meade JL; Cook GP
    Brief Funct Genomic Proteomic; 2008 Jan; 7(1):8-16. PubMed ID: 18208863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.
    Terunuma H; Deng X; Dewan Z; Fujimoto S; Yamamoto N
    Int Rev Immunol; 2008; 27(3):93-110. PubMed ID: 18437601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches using natural killer cells in cancer therapy.
    Suck G
    Semin Cancer Biol; 2006 Oct; 16(5):412-8. PubMed ID: 16914327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.